Co-Diagnostics, Inc. (NASDAQ: CODX) filed a Current Report on Form 8-K on September 16, 2026, announcing that it will host an investor and analyst presentation. The event is scheduled for September 16, 2026, and will cover several key areas of the company's business operations and development.
The presentation materials will focus on the company's collaboration with ReadyGo Diagnostics Ltd. The company will also discuss its Co-Dx PCR platform and related development activities. Additionally, the filing indicates that the presentation will include information regarding manufacturing initiatives and operations in India.
A copy of the presentation materials, designated as Exhibit 99.1, is furnished with the filing and incorporated by reference. The company’s principal executive offices are located at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109.
